Botswana National HIV/AIDS Treatment Guidelines: 2008 Version

Objectives

Botswana’s National HIV/AIDS Treatment Guidelines establish a comprehensive national framework for preventing HIV transmission, diagnosing infection, delivering preventive and supportive care, initiating and monitoring antiretroviral therapy, managing treatment failure and toxicity, addressing tuberculosis and opportunistic infections, and providing differentiated care for women, infants, children and adolescents. The framework seeks to expand care progressively, apply internationally accepted standards in ways suited to Botswana’s experience and resources, and support delivery across public and private sectors.[1][2]

• Strengthen prevention through safe-sex counselling, condom use, partner notification, sexually transmitted infection management, routine opt-out HIV testing, infection-control precautions and male circumcision counselling.[3][4]
• Promote early diagnosis, repeat testing after potential exposure, retesting during late pregnancy or labour, and prompt referral for CD4 assessment and World Health Organization clinical staging.[5][6][7]
• Initiate highly active antiretroviral therapy promptly for eligible adults and adolescents, all HIV-positive infants under 12 months, and older children with advanced clinical or immunological disease.[8][9][10]
• Achieve viral suppression below 400 copies/mL within six months of treatment initiation, thereby restoring immune function, improving quality of life, and reducing HIV-related morbidity and mortality.[11][12]
• Prevent mother-to-child transmission through priority treatment assessment for pregnant women, antenatal and intrapartum antiretroviral interventions, newborn prophylaxis, early infant diagnosis and informed infant-feeding support.[13][14][15][16]
• Reduce illness from tuberculosis, opportunistic infections and other HIV-related conditions through routine screening, prophylaxis, diagnosis, timely treatment and coordinated HIV and tuberculosis care.[17][18][19]
• Preserve future treatment options by identifying virological failure promptly, correcting adherence and other non-resistance causes, using resistance testing where indicated, and reserving specialist-managed salvage therapy for extensive resistance.[20][21][11]

Implementation

Implementation combines standardised clinical pathways, decentralised antiretroviral-clinic delivery, specialist referral and national oversight. The Ministry of Health, the Committee for the Clinical Care of HIV/AIDS in Botswana, private-sector participants, partner institutions and medical-aid schemes contributed to guideline development and implementation; the guidelines were to be disseminated through full manuals, handbooks, flip charts, posters and practitioner training.[1][22]

• Deliver HIV services through routine opt-out testing, post-test counselling, clinical examination, CD4 assessment, World Health Organization staging, preventive care and treatment referral. Testing pathways include rapid testing for people aged 18 months and over, expedited resolution of discordant pregnancy results, and DNA polymerase chain reaction testing for HIV-exposed infants.[5][6][8]
• Tailor antiretroviral regimens to age, maturity, pregnancy, reproductive potential, prior single-dose nevirapine exposure, renal function, anaemia, tuberculosis treatment and prior regimen history. Paediatric care uses weight-based dosing and caregiver support, while pregnancy pathways prioritise timely treatment and AZT-based prevention of mother-to-child transmission where appropriate.[23][24][13][14]
• Provide preventive and supportive care alongside treatment, including cotrimoxazole prophylaxis, tuberculosis screening and preventive therapy, immunisation, nutrition counselling, reproductive counselling, cervical screening, psychosocial support and referrals to social or community services.[25][17][18]
• Monitor treatment through scheduled clinical review, viral-load and CD4 testing, regimen-specific laboratory monitoring, adherence assessment and toxicity surveillance. Adults who sustain viral suppression may move to six-monthly viral-load monitoring, whereas paediatric and adolescent patients generally continue three-monthly viral-load monitoring.[26][27][28]
• Require antiretroviral clinics to maintain timely review of returned laboratory results, particularly viral loads, and act rapidly on abnormal results. Failure to address treatment failure within one week of results becoming available is treated as a serious breach of care standards, and patients should not remain on a failing regimen for over four weeks after failure is identified.[29]
• Establish a Failure Management Clinic and multidisciplinary Failure Management Team at every antiretroviral clinic, led by the clinic director or most experienced HIV clinician and coordinated by a designated focal nurse. Teams include clinicians, nurses, adherence educators, social workers, lay counsellors and pharmacy staff, meet at least every two weeks, and use a standardised registry to document treatment history, laboratory findings, resistance results, adherence factors and interventions.[30][31][32]
• Refer complex cases, second-line failures, suspected resistance, severe toxicity and salvage-treatment decisions to HIV Specialists and the Ministry of Health Resistance Technical Working Group. Darunavir and raltegravir access is controlled through this specialist mechanism.[33][21]
• Control access to Category 2 Special Order antiretrovirals through authorisation by Ministry of Health and NASCOD-designated HIV Specialists, documented forms, pharmacy dispensing arrangements, monthly review by the Ministry of Health BEDAP office, patient registers and stock monitoring to prevent expiry of expensive medicines.[34][35][36]
• Support occupational and sexual-violence exposure management through timely post-exposure prophylaxis, ideally within four hours and no later than 72 hours, accompanied by risk assessment, counselling, follow-up testing, documentation and broader medical and psychosocial care.[37][38][39]

Monitoring & Evaluation

The guidelines establish a clinically focused monitoring system for HIV prevention, diagnosis, antiretroviral therapy, co-infections, maternal and child health, and treatment failure. Programme-wide indicators, surveillance targets, independent evaluation methods and formal reporting frameworks are generally not specified; accountability is principally exercised through clinical follow-up, laboratory review, specialist consultation and facility-level processes.[1][29][30]

• Monitor treatment eligibility and disease progression through World Health Organization clinical staging, CD4 cell count or percentage, clinical history and examination. Patients not yet eligible for highly active antiretroviral therapy require periodic reassessment, generally every six months when CD4 count exceeds 400 cells per microlitre and every three months when it is 250 to 400 cells per microlitre.[8][40]
• Measure viral load at three and six months after treatment initiation. Define virological success as a viral load below 400 copies/mL by six months; thereafter, monitor adults every six months and children and adolescents every three months.[12][27][28]
• Measure CD4 count or percentage at three, six and twelve months after treatment initiation and then six-monthly when immune response is adequate, with more frequent review where illness, detectable viraemia, suspected non-adherence or treatment failure occurs.[41][28]
• Review treatment safety through regimen-specific laboratory monitoring, including creatinine clearance for tenofovir disoproxil fumarate, liver enzymes for relevant antiretroviral and tuberculosis regimens, full blood count where indicated, and lipid monitoring for protease-inhibitor-based therapy.[42][43][26][44]
• Repeat HIV testing after recent high-risk exposure, during pregnancy, and where acute infection or discordant results remain possible. Retest HIV-negative pregnant women at 36 weeks’ gestation or at onset of labour, whichever occurs first.[45][5][13]
• Monitor HIV-exposed infants through early DNA polymerase chain reaction testing, immediate referral after a positive first result, confirmatory testing without delaying treatment, monthly clinical review when results are delayed, and follow-up testing after breastfeeding cessation or at 18 months in specified circumstances.[46][6]
• Require antiretroviral clinics to maintain a sustainable process for reviewing returned laboratory results promptly. Monitoring results, particularly viral loads, should be reviewed within 48 hours, and failure to address treatment failure within one week is identified as a serious breach of care standards.[47][29][48]
• Confirm detectable viral load with a priority repeat test before changing treatment, assess adherence, dosing, interactions, absorption and other non-resistance causes, and repeat testing six weeks after corrective intervention. Persistent viraemia generally triggers regimen change or specialist consultation.[49][20][50]
• Establish a Failure Management Clinic and multidisciplinary Failure Management Team at every antiretroviral clinic within three months of the revised guidance. Teams should meet at least fortnightly, review treatment-failure cases, record consultations and interventions in a standardised Failure Management Registry, and report unusual patterns of failure, toxicity or non-adherence to an HIV Specialist.[30][31][32]
• Use specialist oversight for complex treatment failure, resistance-test interpretation, salvage therapy, significant toxicity, paediatric treatment concerns and selected maternal or tuberculosis-related cases. Special Order antiretroviral approvals and related forms are subject to monthly forwarding to the Ministry of Health for review and verification.[21][51][35][36]
• Monitor tuberculosis and HIV co-infection through symptom screening at every visit, liver-enzyme testing during concurrent or sequential tuberculosis and HIV treatment, and intensified surveillance for hepatotoxicity and immune reconstitution inflammatory syndrome.[19][52]
• Maintain targeted monitoring for opportunistic infections and preventive care, including tuberculosis screening, cotrimoxazole prophylaxis eligibility, annual cervical screening for women living with HIV, and clinical monitoring for cryptococcal meningitis, pneumonia and other serious HIV-related conditions.[17][18][53][54]
• Document maternal prevention-of-mother-to-child-transmission referrals in the Obstetrics Record Book, escalate delayed CD4 results for pregnant women, and monitor infant and maternal treatment pathways through repeat testing, clinical assessment and specialist referral.[13][55]

Costing & Financing

The guidelines provide very limited explicit financial information. They emphasise using available resources efficiently, adapting international standards to Botswana’s resource context, controlling access to costly specialist antiretrovirals, and preventing medicine expiry through stock management. They do not set out a programme budget, quantified financing gap, recurrent-cost estimate, allocation, resource-mobilisation plan or economic assumptions.[1][56][34][36]

• Recognise that BOTUSA and the President’s Emergency Plan for AIDS Relief provided a grant for initial printing of the guidelines, while the KITSO Training Program supported editorial work and printing of additional handbooks; no grant amounts are specified.[22]
• Identify abacavir cost as prohibitive for routine adult use in the national programme, influencing the recommended adult second-line regimen.[56]
• Link future selection between emtricitabine and lamivudine to cost, supply and availability considerations, without specifying prices or procurement budgets.[56]
• Control Special Order medicines through specialist authorisation, designated storage sites, monthly pharmacy stock review and return of unused stock to CMS to avoid expiry of expensive medicines.[34][35][36]
• Note resource implications without cost estimates for laboratory monitoring, specialist review, paediatric formulations, formula-feeding support, transfusion support and medicines for opportunistic infections.[14][57][53][58]